Literature DB >> 11410888

The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery.

S T Chao1, J H Suh, S Raja, S Y Lee, G Barnett.   

Abstract

Radiation necrosis and recurrent brain tumor have similar symptoms and are indistinguishable on both magnetic resonance imaging (MRI) and computed tomograph scans. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been proposed as a diagnostic alternative, particularly when co-registered with MRI. We studied 47 patients with brain tumors treated with stereotactic radiosurgery and followed with FDG PET. For all tumor types, the sensitivity of FDG PET for diagnosing tumor was 75% and the specificity was 81%. For brain metastasis without MRI co-registration, FDG PET had a sensitivity of 65% and a specificity of 80%. For brain metastasis with MRI co-registration, FDG PET had a sensitivity of 86% and specificity of 80%. MRI co-registration appears to improve the sensitivity of FDG PET, making it a useful modality to distinguish between radiation necrosis and recurrent brain metastasis. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11410888     DOI: 10.1002/ijc.1016

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  95 in total

1.  Relapsing tumefactive lesion in an adult with medulloblastoma previously treated with chemoradiotherapy and stem cell transplant.

Authors:  Ali Mahta; Yan Qu; Denis Nastic; Maria Sundstrom; Ryan Y Kim; Marlon Saria; Sandro Santagata; Santosh Kesari
Journal:  Pathol Oncol Res       Date:  2011-09-28       Impact factor: 3.201

Review 2.  [Neurological complications of neurooncological therapy].

Authors:  U Herrlinger; J P Steinbach
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

3.  Diagnostic Accuracy of PET, SPECT, and Arterial Spin-Labeling in Differentiating Tumor Recurrence from Necrosis in Cerebral Metastasis after Stereotactic Radiosurgery.

Authors:  G Lai; A Mahadevan; D Hackney; P C Warnke; F Nigim; E Kasper; E T Wong; B S Carter; C C Chen
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-01       Impact factor: 3.825

Review 4.  Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Authors:  Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-02-24       Impact factor: 4.130

5.  Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis.

Authors:  Mark E Mullins; Glenn D Barest; Pamela W Schaefer; Fred H Hochberg; R Gilberto Gonzalez; Michael H Lev
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

Review 6.  Radiotherapy and chemotherapy of brain metastases.

Authors:  R Soffietti; A Costanza; E Laguzzi; M Nobile; R Rudà
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

7.  Is current imaging good enough to differentiate radiation-induced brain injury from tumor recurrence?

Authors:  Wan-Yuo Guo
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

Review 8.  Recent advances in the treatment of oligodendrogliomas.

Authors:  Mark Agulnik; Warren P Mason
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

Review 9.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

Review 10.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.